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Summary
Objective: Disturbances of the proteoglycan metabolism play an essential role in the pathology of osteoarthritis. The extracellular matrix
proteoglycan, perlecan, has lately been identiﬁed as a cell biological factor in cartilage development and maintenance. We investigated the
tissue distribution of perlecan, the relation between the level of the protein and its mRNA and which type of cell, type 1 chondrocytes or
elongated secretory type 2 cells, produces perlecan in late stages of osteoarthritis.
Methods: In 10 patients suffering from late-stage osteoarthritis tissue samples taken from a macroscopically intact area and the area adjacent
to the main cartilage defect were investigated. We performed quantitative immunogold histochemistry and in situ hybridization in vivo and
determined the level of perlecan mRNA with the help of real-time RT-PCR in native cartilage tissue and in cultured cells.
Results: In vivo, an increased level of perlecan protein was found in the area adjacent to the main defect. A 45% rise in the level of perlecan
mRNA secreted by elongated secretory type 2 cells in comparison to type 1 chondrocytes was detected. Type 2 cells also translated the
highest levels of perlecan to be deposited mainly in the pericellular matrix, and also in the interterritorial matrix in late stages of osteoarthritis.
Also in vitro, type 2 cells showed a 50% higher level of mRNA for perlecan.
Conclusion: We found evidence that perlecan is involved in the pathogenesis of late stages of osteoarthritis. The levels of perlecan protein and
mRNA are up-regulated especially by the elongated secretory type 2 cells in the area adjacent to the main cartilage defect. This might be seen
as an attempt on the part of the cartilage tissue to stabilize the extracellular matrix.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Articular cartilage is a highly specialized connective tissue,
which covers the articulating ends of long bones1. The
resilience, integrity and function of articular cartilage are
guaranteed by the content and organization of the abundant
extracellular matrix composed of a system of collagen ﬁbrils
in which a network of proteoglycans is embedded2. The
chondrocytes, responsible for production, organization and
maintenance of the extracellular matrix, constitute only
5e10% of the tissue volume and lack direct cellecell
contacts3,4.
Normal adult hyaline cartilage contains types II, VI, IX, X
and XI collagen, the greatest amount being collagen type II5.
Collagen types II, IX and XI form ﬁbrillar alloys with type XI
as core and collagen type IX on the outside possibly limiting
the ﬁber diameter1,6,7. The other important cornerstones of
the extracellular matrix are the proteoglycans. They all
consist of a core protein containing one or more glycosami-
noglycan side chains8. With reference to the nature of their
core proteins it is possible to allocate each proteoglycan to
one of the several classes9, for example, large proteogly-
cans, such as aggrecan10 and small proteoglycans such as
ﬁbromodulin, epiphycan, decorin and biglycan9,11,12.
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Received 2 March 2004; revision accepted 20 July 2004.85Perlecan, as a new member of the proteoglycans found in
cartilage13, is a large heparan sulfate proteoglycan present
in all basement membranes14. It has been shown that
perlecan is prominent in cartilage9,13 and is enriched mainly
in the pericellular environment of the chondrocytes15,16,
suggesting a role in the attachment of chondrocytes to their
own matrix13. The perlecan core protein is involved in the
control of important biological functions such as cell
adhesion17, maintenance of the extracellular matrix18,19,
binding to growth factors20, cartilage development21 and
regulation of chondrocyte differentiation22. The perlecan
gene encodes an approximately 467 kDa protein core
consisting of ﬁve distinct domains. The N-terminal domain
I is unique to perlecan, whereas domains IIeV share
sequence similarities with other cell surface and extracel-
lular matrix proteins23. Domain I contains a cluster of three
potential glycosaminoglycan attachment sites usually oc-
cupied by heparan sulfate side chains and may play an
important role in chondrocyte differentiation and cartilage
development24. Furthermore, mutations in perlecan lead to
skeletal disorders. The relatively mild SchwartzeJampel
syndrome as well as the neonatal lethal dyssegmental
dysplasia of the SilvermaneHandmaker type show disor-
ganization of the articular cartilage structure15,25.
Up to the present, nothing is known about the role of
perlecan in osteoarthritis (OA), but important biological
functions of this proteoglycan have already been estab-
lished and it is possible that perlecan is involved in the
pathophysiology of this disease. OA is an almost universal,
slowly progressive degenerative process, which may take
years to develop. The centre of the pathogenesis of OA is2
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the osteoarthritic process seems to be in the articular
cartilage itself, i.e. to involve the chondrocytes and their
surrounding matrix27. Further steps in the progress of this
disease are the disruption of the matrix framework and the
increasing water content followed by a loss of matrix
strength28. A loss of the proteoglycans, aggrecan and
decorin, collagen ﬁber ﬁbrillation and surface splits occur
in early stages of OA26,29. An initially increased production of
collagen type II has been detected only in early disease
stages30. In contrast, late stages of OA show a mixture of re-
and degeneration processes31,32. One indication of this is
the occurrence of three main types of chondrocytes, which
have been identiﬁed in osteoarthritic cartilage at the
ultrastructural level33. Type 1 chondrocytes show a typical
chondrocyte phenotype and may be arranged in clusters.
These cells are mainly found in the macroscopically intact
area of osteoarthritic cartilage. The elongated secretory type
2 cells, which have an irregular shape with a prominent
rough endoplasmic reticulum, are mainly found in the deep
zones of articular cartilage of the areas adjacent to the main
defect. Degenerative type 3 cells are mainly found in the
main defect itself and undergo degradation33e35. At the
more advanced stages of OA, elongated secretory type 2
cells express collagens, such as collagen types I and III32,35
while the amounts of collagen type II are decreased26. The
levels of transcription and translation for decorin and
biglycan are also up-regulated in these cells34. Furthermore,
ﬁssures extending deep into the cartilage substance and cell
cluster formation occur. These stages of disease are driven
by degenerative processes catalyzed by tissue pro-
teases29,36, ﬁnally leading to the destruction of the articular
cartilage with denudation of the subchondral bone37.
In the present study, we investigated the levels of
perlecan protein and mRNA and their distribution in the
different chondrocyte cell types33,34 of late-stage osteoar-
thritic cartilage from human knee joints. For in vivo
analysis, we performed light and electron microscopic
immunohistochemistry and in situ hybridization, as well as
real-time RT-PCR to quantitate the level of mRNA.
Furthermore, we isolated the two cell types from osteoar-
thritic tissue taken from the patients and cultivated them
separately. We also applied real-time RT-PCR to quanti-
tate the level of mRNA produced by these two cell types
in vitro.
Materials and methods
TISSUE SAMPLES
Adult osteoarthritic articular cartilage was obtained from
the knee joints of 10 patients (age range 63e79 years)
undergoing an operation for a total knee arthroplasty.
Tissue specimens were collected from a region directly
adjacent to the main defect and from a macroscopically
intact region at the lateral border of the joint. The patients
were suffering from late-stage OA and all met the American
College of Rheumatology classiﬁcation criteria38. Healthy
control cartilage from a 50-year-old accident victim was also
investigated. Patients gave their written informed consent
according to the Ethics Regulations of the Medical Faculty
of the Georg-August University Goettingen.
TISSUE PREPARATION AND SECTIONING
Specimens of articular cartilage were ﬁxed in a for-
maldehyde solution, decalciﬁed, dehydrated and ﬁnallyembedded in parafﬁn for light microscopic investigations39.
Afterwards, sections (4e5 mm) were cut and transferred onto
slides. For topographical orientation and pathohistological
grading, we stained the sections with Alcian blue and
hematoxylineeosin (H.E.). For electron microscopy, we
exclusively investigated specimens from the radial zone
adjoining the tidemark. Tissue samples (1 mm3)were cut and
ﬁxed for 15 min in 4% paraformaldehyde and 0.5% glutaral-
dehyde in phosphate-buffered saline (PBS) at 4(C. The
tissuespecimenswereembedded in thehydrophilic resin LR-
Gold (London Resin Company, Reading, UK) as previously
described35. Subsequently, ultrathin sections (80 nm) were
cut and collected on formvar coated nickel grids.
ANTIBODIES
Anti-DIG antibody (sheep IgG) was obtained from
Quartett, Berlin, and an afﬁnity-puriﬁed goat-anti-rabbit
IgG from Medac, Hamburg. Each of them was coupled to
16 nm colloidal gold particles according to standard proto-
cols34. Furthermore, we used an anti-DIG phosphatase-
labeled antibody from Roche Diagnostics, Heidelberg, for
light microscopic in situ hybridization and a well-character-
ized, afﬁnity-puriﬁed rabbit antibody against perlecan17.
LIGHT AND ELECTRON MICROSCOPIC
IMMUNOHISTOCHEMISTRY
We performed the peroxidase anti-peroxidase (PAP)
method with DAB substrate as described previously39 and
applied the primary antibody against perlecan diluted 1:50
in 1% BSA/PBS at RT for 15 h. For electron microscopic
immunogold histochemistry, the goat-anti-rabbit IgG was
labeled with gold particles as previously described34,35.
Ultrathin tissue sections were incubated with the anti-
perlecan antibody diluted 1:50 in PBS for 1 h at RT. The
secondary gold-coupled antibody, diluted 1:300 in PBS,
was applied for 20 min at RT. Staining with uranyl acetate
followed and reactions were examined with the help of
a Zeiss EM 906E electron microscope.
CONTROLS
For the PAP method, negative controls were performed
by treating the sections with 1% PBS/BSA instead of the
primary antibody and by carrying out only the DAB reaction.
For the control for the immunogold histochemistry the tissue
samples were incubated with pure gold solution in order to
exclude unspeciﬁc binding of free colloidal gold. Further-
more, the reactions were performed with gold-coupled goat-
anti-rabbit IgG to exclude non-speciﬁc IgG binding.
STATISTICAL ANALYSIS
Micrographs of the two different cell types from all
patients (nZ 10) were pooled. Mean values of the numbers
of gold particles per cell (with S.E.M. ranging from 1 to 2)
were analyzed in an area of 2000 nm2 around 10 cells from
each patient. Signiﬁcant differences in the number of gold
particles were noted for P-values (P% 0.001) using the
WilcoxoneManneWhitney test for unpaired samples.
PROBE PREPARATION
RNA was isolated as described below and re-
verse transcribed into perlecan-speciﬁc cDNA. PCR was
854 F. Tesche and N. Miosge: Perlecan in Osteoarthritisperformed with primers speciﬁc for perlecan and a T3-
promoter sequence 5#-CAG AGA TGC AAT TAA CCC TCA
CTA AAG GGC TCG GGG CGA ACT GAT GGT A-3# (a
reverse primer) and a T7-promoter sequence 5#-CCA AGC
TTC TAA TAC GAC TCA CTA TAG GGA CCT TCG CTG
GCT CAA GGA G-3# (a forward primer) to insert the
promoter sequences. Afterwards, in vitro transcription of
non-radioactive sense and antisense RNAs with a digox-
igenin labeling kit (Boehringer DIG-RNA labeling kit,
Boehringer, Mannheim, Germany) was performed applying
the T3- and T7-polymerases (Gibco/BRL, Heidelberg,
Germany). Following extraction of the probes with phenole
chloroform these were precipitated with absolute ethanol
and dissolved in DEPCeH2O.
LIGHT AND ELECTRON MICROSCOPIC IN SITU HYBRIDIZATION
For light microscopic investigations, parafﬁn sections
were deparafﬁnized, rehydrated and pre-treated with pro-
teinase K. For the hybridization, the probe concentration
was 100 ng digoxigenin-labeled antisense probe for perle-
can in 100 ml hybridization solution (50% formamide, 5!
SSC, 0.1 mg/ml yeast-RNA, 10 ng/ml probe) for each
section. Hybridization was carried out for 16 h at 50(C.
Posthybridization treatment included a washing procedure
with 4! SSC (3! 10 min, at 50(C), 2! SSC (1! 15 min,
at 60(C), 0.1! SSC (1! 15 min, at 60(C) and 0.05!
SSC (1! 15 min, at 60(C). Afterwards the incubation with
Fig. 1. Radiograph of a patient suffering from late-stage OA.
Regions from which the tissue samples were taken are an area
adjacent to the main defect (black arrow) and a macroscopically
intact area (open arrow); barZ 2 cm.the anti-DIG phosphatase-labeled antibody diluted 1:300 in
PBS was started. Finally color reactions were started with
NBT/BCIP substrate. For electron microscopy, nickel grids
were incubated with the same hybridization solution as
described above for 19 h at 50(C. Probe concentration for
perlecan was 100 ng digoxigenin-labeled antisense probe
in 20 ml hybridization solution per grid. Rinsing steps were
the same as described above. Afterwards, sections were
incubated with the gold-coupled anti-DIG antibody in PBS
(diluted 1:60) for 1 h at RT. The specimens were rinsed with
PBS, contrasted and analyzed with the Zeiss EM 906E.
CONTROLS
Each hybridization was accompanied by a hybridization
with an equivalently labeled amount of sense probe.
Furthermore, hybridizations were performed without any
RNA probes. Additionally, for the ultrastructural controls,
tissue sections were treated with pure gold solution or the
coupled anti-DIG antibody alone.
STATISTICAL ANALYSIS
For in situ hybridization at the ultrastructural level,
micrographs of the two different cell types from patients
(nZ 6) were pooled and counted for gold particle contents.
Mean values of the numbers of gold particles per cell (with
S.E.M. ranging from 1 to 3) were analyzed in an area of
2000 nm2 in 10 cells from each patient. Signiﬁcant differ-
ences in the number of gold particles were noted for
P-values (P% 0.01) using the WilcoxoneManneWhitney
test for unpaired samples.
CELL CULTURE
Two 0.5 cm3 pieces of osteoarthritic cartilage tissue, one
from an area adjacent to the main defect and one from
a macroscopically intact area, from each of the four patients
were minced and cells were isolated by treatment with
collagenase type II (2 mg/ml, Sigma) in DMEM-F12 medium
supplemented with 20% FSC and 100 mmol ascorbic acid
overnight at 37(C and 5% CO2. Thereafter, the suspension
was centrifuged and the cells transferred to culture ﬂasks
coated with ﬁbronectin in PBS (0.01 mg/25 cm2). After
a 10 h incubation period, the supernatant containing the
type 1 chondrocytes was decanted into a new ﬂask, while
the elongated secretory type 2 cells already attached to the
substratum remained in the ﬁrst ﬂask. After approximately
Table I
Data of patients with advanced stages of osteoarthritis of the knee
joint
Patient Sex Age Height
(cm)
Weight
(kg)
Pain
1 Female 79 170 75 RestC load
2 Female 63 165 84 RestC load
3 Female 73 170 95 RestC load
4 Male 75 168 78 Rest
5 Male 71 175 80 Load
6 Female 64 168 75 RestC load
7 Female 68 170 73 Load
8 Female 67 148 57 Rest
9 Male 75 168 82 Load
10 Female 67 169 75 RestC load
Mean values 70.2 167.1 77.4
855Osteoarthritis and Cartilage Vol. 12, No. 11Fig. 2. Histological evaluation of the cartilage samples with H.E. (AeC) and Alcian blue staining (DeF); barsZ 70 mm. (A, D) Tissue samples
from normal physiological cartilage with a homogeneously stained extracellular matrix. (B, E) Specimen taken from the macroscopically intact
area of OA tissue. Note that only a few cells are arranged in clusters. (C, F) Cartilage samples from the area adjacent to the main defect. Note
the increasing number of chondrocytes arranged in clusters, tidemark duplication, loss of the superﬁcial zone, and the overall decreased
Alcian blue staining with intense staining around the cell clusters.2e3 weeks, when near conﬂuence was reached, cells were
harvested to isolate RNA.
RNA EXTRACTION FROM NATIVE CARTILAGE TISSUE
For the extraction of RNA from the native tissue, three
cartilage tissue samples, each approximately 20 mg wet
weight, were taken from each of three patients from the area
adjacent to the main defect and from amacroscopically intact
region at the lateral border of the joint andwere frozen in liquid
nitrogen, pulverised with a mortar and pestle, mixed in
TRIZOL (Biozol, Germany) and incubated for 10 min at RT.
After a centrifugation step the aqueous phasewas transferred
to an RNAeasy Mini-column (RNAeasy Mini Kit, Qiagen) and
processed according to the manufacturer’s instructions.
RNA EXTRACTION FROM CULTURED CELLS AND RT
RNA from the cultured cells was isolated according to the
manufacturer’s instructions (RNAeasy Mini Kit, Qiagen); allRNA populations were treated with DNAfree (Ambion) and
reverse transcribed with the help of the Advantage RT-for-
PCR Kit (BD Bioscience) applying MMLV reverse transcrip-
tase and oligo(dT)18 primer.
PCR
PCR conditions were optimized by applying the gradient
function of the DNA engine Opticon 2 (MJ Research) for
HPRT-1 (NM_000194)40,41 and, for perlecan (M85289),
primers ( forward TCA GTC CCT TGT CAC CAT CCA,
reverse TAA GCT GCC TCC ACG CTT AT) to amplify
a 180 bp transcript were designed by the primer3
shareware. HPRT-1 was chosen as house-keeping gene
because it has been described as being unregulated in
many instances40,41 and was proved to be unregulated
particularly in our experimental setting. The PCR was
performed in a total volume of 50 ml with 200 ng cDNA
derived from the type 1 chondrocytes or the elongated
secretory type 2 cells, 5 ml 10! reaction buffer, dNTP
856 F. Tesche and N. Miosge: Perlecan in OsteoarthritisFig. 3. Light microscopic immunohistochemistry (A, B) and in situ hybridization (C); barsZ 70 mm, inset barsZ 10 mm. (A) Staining for
perlecan is detectable in the pericellular matrix around the cells from the radial zone and to a lesser extent from the cells of the transitional
zone; inset: higher magniﬁcation of a chondrocyte from the radial zone. (B) Staining is more intense in the area adjacent to the main defect,
especially in the surrounding matrix of chondrocytes arranged in clusters (arrow); inset: higher magniﬁcation of a chondrocyte from the radial
zone. Furthermore, staining for perlecan is detectable in the interterritorial matrix. (C) Staining for perlecan mRNA (arrow) in chondrocytes
arranged in clusters; left inset: higher magniﬁcation of a cluster with intense intracellular staining, right inset: control section with a sense
probe.10 mmol each, 20 pmol of each primer, 2.5 U hotstar Taq
DNA polymerase (Qiagen) with the DNA engine Opticon 2
(MJ Research). After an initial activation step of 15 min at
95(C, further steps were as follows: 35 cycles of denaturing
30 s at 94(C, annealing 30 s at 61(C and elongation for 30 s
at 72(C and, ﬁnally, extension for 10 min at 72(C. A total of
10 ml of each sample was loaded on a 1.5% agarose gel,
and visualized by ethidium bromide after electrophoresis.
REAL-TIME PCR
In order to optimize the real-time PCR conditions for
quantiﬁcation, the optimal MgCl2 concentration was de-
termined. A total of 12.25 ml of 2! QuantiTect SYBR Green
PCR Master Mix (Qiagen), 20 pmol of each primer and
250 ng of cDNA were added to a ﬁnal volume of 25 ml.
Cycling was performed following the protocol described
above. Data acquisition was carried out after each
extension step and a melting curve was performed in
0.1(C steps from 50(C to 95(C. Real-time PCR efﬁcien-
cies were calculated from the given slopes in Opticon 2
Monitor software42. Real-time PCR efﬁciency rates were
high with values of 1.97. Experiments were performed four
times in triplicate; the inter-test variation was %2.5% and
the intra-test variation %1.2%. One PCR product was
puriﬁed and sequenced to conﬁrm that the nucleotide
sequence was that of perlecan.
Results
PATIENT DATA
Macroscopically, all tissue samples from the patients
revealed advanced OA with sclerosis and joint space
narrowing (Fig. 1). Pathohistologically they could be
classiﬁed as OA grades IIIeIV43. All patients suffered from
load or rest-pain of the knee. No obvious correlationbetween age, sex, weight, height, or clinical condition was
detectable (Table I).
LIGHT MICROSCOPIC HISTOLOGY
The physiological normal control cartilage sections,
obtained from a 50-year-old male accident victim, revealed
a homogeneously stained matrix and a normal structure of
articular cartilage following H.E. [Fig. 2(A)] and Alcian blue
staining [Fig. 2(D)]. The specimens taken from the
macroscopically intact cartilage areas of the patients with
late-stage OA exhibited an increased number of cells, i.e.
diffuse hypercellularity, and a small number of cells
arranged in clusters [Fig. 2(B)]. Furthermore, reduced
Alcian blue staining, indicating a loss of glycosaminogly-
cans, was detected [Fig. 2(E)]. The tissue samples from the
area adjacent to the main defect revealed ﬁssured cartilage
tissue, an increased number of clusters [Fig. 2(C)] and
reduced staining for Alcian blue [Fig. 2(F)].
LIGHT AND ELECTRON MICROSCOPIC
IMMUNOHISTOCHEMISTRY
Light microscopic immunohistochemistry of the cartilage
tissues revealed mainly pericellular staining for perlecan in
all samples investigated. Specimens taken from the
macroscopically intact areas [Fig. 3(A)] or from the healthy
control cartilage (data not shown) showed strong staining in
the pericellular matrix of the radial zone and weaker staining
in the transitional zone. In contrast to the two zones
described above, no staining for perlecan was detected in
the superﬁcial layer of articular cartilage. Furthermore,
specimens taken from the area adjacent to the main defect
revealed staining for the perlecan protein also in the
interterritorial matrix and exhibited a more intense staining
for perlecan than the specimens from the macroscopically
857Osteoarthritis and Cartilage Vol. 12, No. 11intact areas. The highest staining intensity was located in
the surrounding matrix of chondrocytes organized in
clusters [Fig. 3(B)]. Due to difﬁculties involved in differen-
tiation between type 1 and type 2 cells at the light
microscopic level we performed investigations at the
ultrastructural level. Ultrastructurally, the macroscopically
intact areas revealed chondrocytes of normal phenotype
with sparse, ﬁnely structured endoplasmic reticulum. These
type 1 cells with numerous ﬁlopodia were embedded in
a homogeneous extracellular matrix with collagen ﬁbers
and proteoglycans [Fig. 4(A)]. The area adjacent to the
main defect showed irregular, elongated cells containing
large amounts of a prominent and enlarged rough endo-
plasmic reticulum [Fig. 4(B)] and was classiﬁed as
elongated secretory type 2 cells33,34. In agreement with
the results from the light microscopic immunohistochemistry
we detected higher perlecan protein amounts at the
ultrastructural level in the interterritorial matrix of the
cartilage tissue samples taken from the area adjacent to
the main defect where perlecan was found close to thin
collagen ﬁbers [Fig. 4(C)]. Similarly, immunogold histo-
chemistry revealed staining for perlecan mainly in the
extracellular matrix which directly surrounds the chondro-
cytes, i.e. the pericellular matrix, for type 1 cells [Fig. 5(A)]
and type 2 cells [Fig. 5(B)]. The staining intensity was
highest in the pericellular matrix of elongated secretory type
2 cells. Quantitation of the results of the immunogold
histochemistry revealed a 20e30% higher amount of
perlecan protein in the pericellular matrix surrounding the
secretory type 2 cells as compared with the normal type 1
cells with P-values %0.001 [Fig. 6(A)].
CONTROLS
Neither the negative controls performed at the light
microscopic level nor the control sections at the ultrastruc-
tural level incubated with pure gold solution or gold-coupled
goat-anti-rabbit IgG revealed any reaction.
LIGHT AND ELECTRON MICROSCOPIC IN SITU HYBRIDIZATION
The cartilage samples investigated with light microscopic
in situ hybridization exhibited an intracellular staining for
perlecan mRNA in all specimens. As expected, only the
nuclei of the chondrocytes and the extracellular matrix
remained unstained. The tissue samples taken from the
area adjacent to the main defect exhibited a more
intensive staining than those taken from the macroscop-
ically intact areas of articular cartilage from OA patients or
healthy control cartilage (data not shown). A specimen
from the area adjacent to the main defect is shown for
perlecan mRNA staining in the cytoplasm of chondrocytes
arranged in clusters [Fig. 3(C) and left inset]. Control
hybridizations performed with an equivalent amount of
sense probes remained negative [Fig. 3(C), right inset]. At
the ultrastructural level, sparse staining for perlecan
mRNA was detected in type 1 cells [Fig. 5(C)], while
a greater number of gold particles were seen in the
cytoplasm of type 2 cells [Fig. 5(D)]. Labeling was
detected at the border of the rough endoplasmic reticulum
in the cytoplasm of the chondrocytes classiﬁed as type 1
cells [Fig. 5(E)] and to a greater extent in type 2 cells
[Fig. 5(F)]. Control hybridizations with sense probes were
performed but neither for type 1 cells [Fig. 5(G)] nor for
type 2 cells [Fig. 5(H)] was any staining detectable.Quantitation of the results of the ultrastructural in situ
hybridization revealed an approximately 45% higher
amount of perlecan mRNA in the elongated secretory
type 2 cells than in the type 1 cells with P-values %0.01
[Fig. 6(B)].
Fig. 4. Electron micrographs of the two different cell types (A, B)
and the interterritorial matrix from a tissue sample taken from the
area adjacent to the main defect (C). (A) Type 1 cell; note the round
cell shape, the abundant ﬁlopodia and the ﬁne endoplasmic
reticulum (open arrow). (B) Type 2 cell; note the elongated cell
shape, the sparse podoﬁlia and the dilated endoplasmic reticulum
(open arrow); nZ nucleus, barsZ 0.8 mm. (C) Immunogold histo-
chemistry for perlecan protein. Staining is detectable in the
interterritorial matrix close to thin collagen ﬁbers (black arrows);
barZ 0.3 mm.
858 F. Tesche and N. Miosge: Perlecan in OsteoarthritisFig. 5. Immunogold histochemistry for perlecan protein (A, B) and in situ hybridization for perlecan mRNA (CeH) at the ultrastructural level.
Type 1 cells (A, C, E, G) with multiple ﬁlopodia (asterisks in A) on the cell surface and elongated type 2 cells (B, D, F, H) with few ﬁlopodia
(asterisk in B), barsZ 0.15 mm, except in C and D, barZ 0.3 mm. (A) The pericellular matrix of a type 1 cell exhibits staining for perlecan. (B)
Stronger staining is found for perlecan surrounding a type 2 cell. (C) Staining for perlecan mRNA in the cytoplasm of a type 1 cell (arrow). (D)
Stronger labeling in a type 2 cell (arrow). (E) Higher magniﬁcation of a type 1 cell; note staining for the perlecan mRNA at the border of the
rough endoplasmic reticulum. (F) Higher magniﬁcation of a type 2 cell. (G) Control hybridizations for a type 1 cell and a type 2 cell (H) with the
corresponding sense probe exhibiting no reaction; nZ nucleus.CONTROLS
The control hybridizations performed with a sense probe
or without any RNA probe revealed no reaction. Ultrastruc-
tural control hybridizations were carried out with a sense
probe and exhibited a sparse labeling which could be
regarded as unspeciﬁc background. Treatment of sections
with pure gold solution as well as with gold-coupled anti-
DIG antibody produced no reaction.
RT-PCR AND REAL-TIME PCR
We isolated the cartilage cells from an area adjacent to
the main defect and from a macroscopically intact area andwere able to separate the two cell types detected in vivo by
their kinetics of adherence to the ﬁbronectin substratum of
the culture ﬂask44. The elongated secretory type 2 cells
adhered already after 10 h, while the type 1 chondrocytes
needed at least 24 h for attachment. Therefore, we were
able to culture type 1 and type 2 cells separately. When
near conﬂuence was reached in the ﬁrst passage, we
harvested the cells and isolated the RNA. RT-PCR detected
a slightly thicker band for the perlecan mRNA in type 2 cells
(Fig. 7, lane 2) as compared to the type 1 cells (Fig. 7, lane 1).
We also performed quantitative real-time RT-PCR and
were ﬁrst able to determine an unregulated house-
keeping gene40,41, HPRT-1, with identical ct values of
approximately 24, i.e. the same amounts of transcripts for
859Osteoarthritis and Cartilage Vol. 12, No. 11the type 1 and type 2 cells (Fig. 7, lanes 3 and 4). The
calibrator curve obtained by the correlation of the ct
values (threshold cycles) with the dilution series of the
house-keeping gene exhibits a relatively low intra-test
variation [Fig. 8(A)]. Real-time PCR revealed mean ct
values of 20.9 for perlecan in cultured type 2 cells and of
22.1 for type 1 cells. Applying the calculations of Pfafﬂ42,
this corresponds to a ratio of 0.01 for type 1 cells and
a ratio of 0.02 for type 2 cells and demonstrates a 50%
higher level of perlecan mRNA in type 2 cells (data not
shown). The validity of the PCR results was conﬁrmed by
the melting curve [Fig. 8(B)] and by sequencing the
perlecan product (data not shown). Real-time PCR of the
native cartilage tissue taken from the area adjacent to the
main cartilage defect revealed mean ct values of 28.0
and from a macroscopically intact area of 30.1 [Fig. 8(C)].
This demonstrates a 50% higher level of perlecan mRNA
in the area adjacent to the main cartilage defect taken
from native tissue.
Discussion
According to a well-established grading system, our
specimens were pathohistologically graded and were all
found to be grades IIIeIV, i.e. late stages of OA43. The
osteoarthritic cartilage samples from patients investigated
here showed signs of degeneration and to a lesser extent of
regeneration. As OA is based on multifactorial conditions
with a complex pathogenesis26e38,43, it is very difﬁcult to
achieve a clear histological demarcation between degen-
erative and regenerative changes. For electron microscopic
immunohistochemistry and ultrastructural in situ hybridiza-
tion, we exclusively investigated the deep zones of
osteoarthritic cartilage, i.e. samples from the deep zones
of a macroscopically intact area and an area adjacent to the
main defect. In this region, where the main regeneration
processes take place, we saw mainly elongated secretory
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Fig. 6. (A) Mean values with S.E.M. (T on the bars) of the number of
gold particles for type 1 and type 2 cells representing the amount of
perlecan protein detected by immunogold histochemistry and (B)
of perlecan mRNA detected by ultrastructural in situ hybridization.type 2 cells described several years ago as a sign of the
regeneration efforts of the diseased cartilage tissue31,33e35.
In the present study, we investigated the role of the
proteoglycan perlecan in human knee joint cartilage from
patients suffering from late-stage OA. It is well known that
proteoglycans such as aggrecan, biglycan and decorin are
involved in the pathophysiology of OA26e29. A loss of
decorin and biglycan was described for the superﬁcial
layers of osteoarthritic cartilage29, while an increased
amount of these proteoglycans, as well as an increased
transcription rate, was detected in the deeper zones of
osteoarthritic cartilage. In spite of the overall proteoglycan
loss due to the reduction of the major matrix component
aggrecan in late-stage OA, we also detected increasing
amounts of mRNA of decorin and biglycan in the deep
zones of OA cartilage. Especially the elongated secretory
type 2 cells occurring in late-stage OA revealed an
up-regulated expression of these proteoglycans34.
Our present in vivo analysis at the light and electron
microscopic level revealed a tissue distribution for perlecan
in late stages of OA similar to that described for physio-
logical cartilage13,15,16. Perlecan was mainly found in the
deeper zones of the cartilage and in cell clusters of late
stages of OA. In contrast to normal cartilage, the tissue
samples taken from the area adjacent to the main defect
also revealed staining for perlecan in the interterritorial
matrix, where it was mainly found on ﬁne collagen ﬁbers.
Fig. 7. Conventional RT-PCR; lane 1 shows a band for perlecan
mRNA in type 1 cells, in lane 2 for perlecan in type 2 cells, lane 3 for
the house-keeping gene HPRT-1 in type 1 cells and in lane 4 for
HPRT-1 in type 2 cells. Note that the band in lane 1 seems to be
fainter than in lane 2, but that lanes 3 and 4 exhibit a similar
brightness.
860 F. Tesche and N. Miosge: Perlecan in OsteoarthritisPerlecan knockout mice exhibited reduced amounts of
collagen ﬁbers and a lack of the typical collagen network19
suggesting an important role of this proteoglycan in
maintaining the collagen network in articular cartilage.
Thus, one might assume that the increased levels of
perlecan protein in late stages of OA can be seen as an
effort on the part of the cartilage tissue to stabilize the
extracellular matrix and the collagen ﬁbers embedded in it.
Ultrastructural analysis revealed an approximately 45%
higher mRNA level for perlecan in late stages of OA. Similar
observations have been made for the mRNA levels of the
two small proteoglycans decorin and biglycan in late stages
of OA34. The increase in the level of perlecan protein and
mRNA is achieved by the elongated secretory type 2 cells
Fig. 8. Quantitative real-time RT-PCR data. (A) The calibrator curve
obtained by the correlation of the ct values (threshold cycles) with
the dilution series of the house-keeping gene HPRT-1. (B) Melting
curve for perlecan PCR; the one peak at 86(C for all PCR runs
represents the perlecan product and indicates no other transcripts.
(C) Increasing intensity of ﬂuorescence per PCR cycle for native
cartilage tissue; note that the slopes of the graphs, each color
representing one PCR reaction, are similar and that the thresholds
for RNA isolated from the area adjacent to the main cartilage defect
lie around 28 cycles ( ﬁrst group of curves) and from the
macroscopically intact area lie around 30 cycles (second group of
curves).and these cells deposit perlecan mainly in the pericellular
matrix. This was conﬁrmed by a 50% increase of perlecan
mRNA in vivo taken from native cartilage and in vitro taken
from cultured cells as shown by quantitative real-time RT-
PCR. With regard to the enhanced level of perlecan protein
around chondrocyte clusters adjacent to the cells in the
pericellular matrix, it remains to be seen whether perlecan
shows any mitogenic activity in these late disease stages.
The glycosaminoglycan side chains of perlecan act as
a low-afﬁnity co-receptor for FGFs and mitogenic activity
has already been shown for other cells20. The type 2 cells
which are the only new cells emerging at late stages of OA
and the ones mainly responsible for the regeneration
processes of cartilage matrix33,34 produce more perlecan,
which might be beneﬁcial for the matrix integrity and the
chondrocytes embedded in it. In normal cartilage, perlecan
interacts with other adhesive extracellular macromolecules
to stabilize the matrix and to enable the adhesion of
chondrocytes to their own substratum13,18,19. The role of
collagen type IX, which also shows characteristics of a
proteoglycan, for the structural integrity of the pericellular
matrix has been underlined3. In late stages of OA the
integrity of the pericellular matrix is altered and it would be
interesting to investigate whether the increased amounts of
perlecan shown here can help to stabilize the pericellular
matrix. The increased amount of perlecan protein, espe-
cially in the area next to the main defect, may be seen as
an effort on the part of the cartilage tissue to compensate
for the rapid loss of other matrix molecules such as
aggrecan29.
In conclusion, the results presented here indicate the
involvement of perlecan in the pathogenesis of late stages
of OA. The higher level of perlecan mRNA especially in the
elongated secretory type 2 cells mainly found in the areas
adjacent to the main cartilage defect and the increased
level of perlecan protein mainly deposited in the pericellular
matrix and to a lesser extent in the interterritorial matrix,
might reﬂect an attempt on the part of the cartilage tissue to
stabilize and protect the remaining matrix of late-stage
osteoarthritic cartilage from further destruction.
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